34047-62-6

Usage

Uses

Used in Pharmaceutical Applications:
L-erythro-3-(3,4-Dihydroxyphenyl)serine is used as a therapeutic agent for the treatment of neurological disorders. It has been shown to inhibit methamphetamine-induced locomotor activity and decrease brain dopamine content when administered to rats, suggesting its potential in managing conditions related to dopamine dysregulation.
Used in Research and Development:
L-erythro-3-(3,4-Dihydroxyphenyl)serine is also utilized in research settings to study the effects of various substances on dopamine levels and neurotransmission. Its ability to modulate dopamine content in the brain makes it a valuable tool for understanding the underlying mechanisms of neurochemical interactions and the development of novel treatments for related disorders.

Upstream product

• 5447-02-9 3,4-dibenzyloxybenzaldehyde 
• 113139-62-1 3,4-bis(ethoxycarboxy)-benzaldehyde 
• 50-81-7 ascorbic acid 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 173597-41-6 3,4-Dicarboethoxymethylenedioxybenzaldehyde 
• 55449-18-8 (2RS.3RS)-2-amino-3-(3,4-bis-benzyloxy-phenyl)-3-hydroxy-propionic acid 
• 55449-18-8 D,L-threo-3-(3,4-Dibenzyloxyphenyl)serine 

Relevant academic research and scientific papers

Synthesis of 2- and 6-fluoro analogues of threo-3-(3,4-dihydroxyphenyl)serine (2- and 6-fluoro-threo-DOPS)

2-Fluoro- and 6-fluoro-threo-dihydroxyphenylserine (2-F- and 6-F-threo-DOPS) have the potential, after crossing the blood-brain barrier, of functioning in the central nervous system as biological precursors of 2- and 6-fluoronorepinephrine (2- and 6-F-NE)

Process for producing 3-(3,4-dihydroxyphenyl) serine

A process for producing racemic or optically active threo- or erythro-3-(3,4-dihydroxyphenyl)serine which comprises phthaloylating the amine group of a racemic or optically active threo- or erythro-3-(3,4-dihydroxyphenyl)serine derivative to yield a racem

Process for producing threo-3-(3,4-dihydroxyphenyl)serine

A process for producing an optically active threo-3-(3,4-dihydroxyphenyl)serine represented by the formula STR1 which is useful as a remedy for peripheral orthostatic hypotension or as an antidepressant, which process comprises treating threo-3-(3,4-methy

Process for the production of optically active threo-3-(3,4-dihydroxyphenyl)serine

Improved process for the production of optical aCTIVE (D- or L-) threo-3-(3,4-dihydroxyphenyl)serine, which comprises subjecting racemic threo-3-(3,4-dibenzyloxyphenyl)-N-carbobenzyloxyserine to optical resolution by using as a resolving reagent an optical active amino alcohol derivative, and then subjecting the resulting optical active (D- or L-) threo-3-(3,4-dibenzyloxyphenyl)-N-carbobenzyloxyserine to hydrogenolysis.